Sunstone announce new investment in immuno-oncology company STipe Therapeutics

Copenhagen, 30 September 2019 – Sunstone Life Science Ventures today announce it has invested in new portfolio company Stipe Therapeutics ApS (“STipe”), an immuno-oncology company dedicated to developing novel cancer therapeutics based on its first class drugs modulating the STING pathway.

This is the second investment of its Life Science Ventures Fund IV. The total financing round is €20 million and proceeds from the financing will be used to prepare the company for clinical development.

Press inquiries should be adressed to: